title: Ctrl4
organism: Mus musculus
description: Protocols: Th-MYCNCPM32-model is based on 129X1/SvJ-Tg(TH-MYCN)41Waw/Nci. Homozygote tumour bearing mice for MYCN were subject to individualized dose escalation schedule for cyclophosphamide (CPM) until they acquired resistance to 32mg/kg CPM. Mice included in the study were sacrificed and primary tumours were dissected out. Personalised dose escalation protocol of the chemotherapy drug cyclophosphamide. Homozygote for MYCN leads to 100% tumour penetration at the age 40-89, once the tumour was detected by palpation at a size of 5mm the treatment began. Duration of treatment was between 66-166 days. Dosing was initiated with a single dose of 16 mg/kg. Upon regrowth (following regression in size), the tumor was dosed again with 16 mg/kg. This treatment was repeated until tumors no longer responded to the dose, at which time, the dose was increased by 150%. Studies were terminated when the tumor became resistant to 32 mg/kg CPM and continued to grow to a palpable size of 15 mm or immediately upon showing any signs of ill health. Tumour samples were sent to a commerical sequencing unit which extracted the RNA. TruSeq® Stranded Total RNA according to manufacturers protocol